Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Payables (2016 - 2025)

Historic Payables for STRATA Skin Sciences (SSKN) over the last 14 years, with Q3 2025 value amounting to $3.0 million.

  • STRATA Skin Sciences' Payables rose 6895.37% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 6895.37%. This contributed to the annual value of $2.4 million for FY2024, which is 2722.11% down from last year.
  • As of Q3 2025, STRATA Skin Sciences' Payables stood at $3.0 million, which was up 6895.37% from $2.9 million recorded in Q2 2025.
  • STRATA Skin Sciences' Payables' 5-year high stood at $10.4 million during Q1 2021, with a 5-year trough of $1.7 million in Q3 2024.
  • For the 5-year period, STRATA Skin Sciences' Payables averaged around $3.9 million, with its median value being $3.2 million (2023).
  • Its Payables has fluctuated over the past 5 years, first tumbled by 7695.81% in 2021, then soared by 7616.94% in 2022.
  • STRATA Skin Sciences' Payables (Quarter) stood at $2.8 million in 2021, then rose by 21.37% to $3.4 million in 2022, then decreased by 2.39% to $3.3 million in 2023, then dropped by 27.22% to $2.4 million in 2024, then increased by 21.45% to $3.0 million in 2025.
  • Its Payables was $3.0 million in Q3 2025, compared to $2.9 million in Q2 2025 and $2.8 million in Q1 2025.